Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer by Daniel Stellato, Marroon Thabane, Caitlin Eichten, Thomas E. Delea

Get full text

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. by Jordan Amdahl, Jose Diaz, Arati Sharma, Jinhee Park, David Chandiwana, Thomas E Delea

Get full text

Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia by Anthony J. Hatswell, Gwilym J. Thompson, Penny A. Maroudas, Oleg Sofrygin, Thomas E. Delea

Get full text

Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. by Thomas E Delea, Derek Weycker, Mark Atwood, Dion Neame, Fabián P Alvarez, Evelyn Forget, Joanne M Langley, Ayman Chit

Get full text

Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease by William B. Ershler, MD, Laura M. De Castro, MD, MHSc, Zahra Pakbaz, MD, Aaron Moynahan, MA, Derek Weycker, PhD, Thomas E. Delea, MSIA, Irene Agodoa, MD, Ze Cong, PhD

Get full text